ELANCO ANIMAL HEALTH INC (5EA.DE) Stock Price & Overview

FRA:5EA • US28414H1032

Current stock price

19.75 EUR
-0.3 (-1.52%)
Last:

The current stock price of 5EA.DE is 19.75 EUR. Today 5EA.DE is down by -1.52%. In the past month the price increased by 1.96%.

5EA.DE Key Statistics

1-Month Range19.704 - 22.51
Current 5EA.DE stock price positioned within its 1-month range.
Market Cap
9.819B
P/E
24.09
Fwd P/E
21.69
EPS (TTM)
0.82
Dividend Yield
N/A

5EA.DE Stock Performance

Today
-1.52%
1 Week
-9.05%
1 Month
+1.96%
3 Months
N/A
Longer-term
6 Months N/A
1 Year N/A
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A

5EA.DE Stock Chart

ELANCO ANIMAL HEALTH INC / 5EA Daily stock chart

5EA.DE Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to 5EA.DE.


Chartmill TA Rating
Chartmill Setup Rating

5EA.DE Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to 5EA.DE. 5EA.DE may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

5EA.DE Earnings

On February 24, 2026 5EA.DE reported an EPS of 0.13 and a revenue of 1.14B. The company beat EPS expectations (15.04% surprise) and beat revenue expectations (2.6% surprise).

Next Earnings DateMay 5, 2026
Last Earnings DateFeb 24, 2026
PeriodQ4 / 2025
EPS Reported$0.13
Revenue Reported1.144B
EPS Surprise 15.04%
Revenue Surprise 2.60%

5EA.DE Forecast & Estimates

22 analysts have analysed 5EA.DE and the average price target is 22.49 EUR. This implies a price increase of 13.88% is expected in the next year compared to the current price of 19.75.

For the next year, analysts expect an EPS growth of 10.73% and a revenue growth 7.56% for 5EA.DE


Analysts
Analysts85.45
Price Target22.49 (13.87%)
EPS Next Y10.73%
Revenue Next Year7.56%

5EA.DE Groups

Sector & Classification

Sub-Industry
Pharmaceuticals
Index Membership

5EA.DE Financial Highlights

Over the last trailing twelve months 5EA.DE reported a non-GAAP Earnings per Share(EPS) of 0.82. The EPS increased by 4.4% compared to the year before.


Income Statements
Revenue(TTM)4.71B
Net Income(TTM)-232.00M
Industry RankSector Rank
PM (TTM) N/A
ROA -1.74%
ROE -3.54%
Debt/Equity 0.6
Chartmill High Growth Momentum
EPS Q2Q%-7.14%
Sales Q2Q%12.16%
EPS 1Y (TTM)4.4%
Revenue 1Y (TTM)6.22%

5EA.DE Ownership

Ownership
Inst Owners109.64%
Shares497.17M
Float491.03M
Ins Owners0.98%
Short Float %N/A
Short RatioN/A

About 5EA.DE

Company Profile

5EA logo image Elanco Animal Health, Inc. develops, manufactures, and markets products for pets and farm animals. The company is headquartered in Indianapolis, Indiana and currently employs 9,400 full-time employees. The company went IPO on 2018-09-20. The firm's product portfolio is sold in more than 90 countries and serves animals across many species, primarily dogs and cats (collectively, pet health) and cattle, poultry, swine, and sheep (collectively, farm animal). The company has a diverse portfolio of products marketed under approximately 200 brands, including products for both pets and farm animals. The firm's global pet health portfolio is focused on parasiticides, vaccines and therapeutics. Its pet health products include Advantage Family, Atopica, Credelio Family, Drontal Family, Galliprant, Interceptor Plus, Milbemax, Onsior, Seresto, Trifexis, and TruCan. Its farm animal products include AviPro, Baytril, Catosal, Denagard, Experior, Hemicell, Maxiban/Monteban, Pulmotil, Rumensin, and Surmax. Its customers include consultants, veterinarians, farm animal producers and resellers.

Company Info

IPO: 2018-09-20

ELANCO ANIMAL HEALTH INC

450 Elanco Circle

Indianapolis INDIANA US

Employees: 9225

5EA Company Website

5EA Investor Relations

Phone: 18773526261

ELANCO ANIMAL HEALTH INC / 5EA.DE FAQ

Can you describe the business of ELANCO ANIMAL HEALTH INC?

Elanco Animal Health, Inc. develops, manufactures, and markets products for pets and farm animals. The company is headquartered in Indianapolis, Indiana and currently employs 9,400 full-time employees. The company went IPO on 2018-09-20. The firm's product portfolio is sold in more than 90 countries and serves animals across many species, primarily dogs and cats (collectively, pet health) and cattle, poultry, swine, and sheep (collectively, farm animal). The company has a diverse portfolio of products marketed under approximately 200 brands, including products for both pets and farm animals. The firm's global pet health portfolio is focused on parasiticides, vaccines and therapeutics. Its pet health products include Advantage Family, Atopica, Credelio Family, Drontal Family, Galliprant, Interceptor Plus, Milbemax, Onsior, Seresto, Trifexis, and TruCan. Its farm animal products include AviPro, Baytril, Catosal, Denagard, Experior, Hemicell, Maxiban/Monteban, Pulmotil, Rumensin, and Surmax. Its customers include consultants, veterinarians, farm animal producers and resellers.


What is the current price of 5EA stock?

The current stock price of 5EA.DE is 19.75 EUR. The price decreased by -1.52% in the last trading session.


What is the dividend status of ELANCO ANIMAL HEALTH INC?

5EA.DE does not pay a dividend.


What is the ChartMill technical and fundamental rating of 5EA stock?

5EA.DE has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


Can you provide the growth outlook for ELANCO ANIMAL HEALTH INC?

The Revenue of ELANCO ANIMAL HEALTH INC (5EA.DE) is expected to grow by 7.56% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.


What is the market capitalization of 5EA stock?

ELANCO ANIMAL HEALTH INC (5EA.DE) has a market capitalization of 9.82B EUR. This makes 5EA.DE a Mid Cap stock.


What is the next earnings date for 5EA stock?

ELANCO ANIMAL HEALTH INC (5EA.DE) will report earnings on 2026-05-05, before the market open.